October 4, 2018 - Biopharma Pioneer Returns to Small Company Roots - Interview with Dr. David Stirling, CEO BioTheryX Inc.
August 26, 2018 - New 'cluster bomb-like' drug could become cure for acute leukemia.
August 24, 2016 - Cure for acute leukemia within reach.
August 23, 2018 - Publication in the scientific journal Cell Titled "Small Molecules Co-targeting CKI(Alpha) and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models" highlights BioTheryX's lead clinical candidate that may become the most significant treatment for patients with devastating cancers such as AML in 40 years.
December 11, 2017 - Oral presentation at the 59th American Society of Hematology (ASH) meeting. Abstract #100527 titled: Targeting the Transcriptional Addiction of Leukemia Stem Cells By a New Class of Protein Kinase Inhibitors.
December 11, 2017 - Poster presentation at the 59th American Society of Hematology (ASH) meeting. Abstract #102856 titled: Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma.
June 23, 2017 - Presidential Symposium, late-breaking abstract presentation at the 22nd European Hematology Association (EHA) meeting. Abstract #LB2600 Titled: Novel Small Molecule Inhibitors Co-Targeting CK1A and P-TEFb Disrupt Super-Enhancers and Eradicate Acute Myeloid Leukemia in a Mouse Model.
BioRap and BioTheryX Sign Strategic Collaborative Agreement for the Development of Novel Protein Degradation Compounds for the Treatment of Cancer and Immune DisorderSan Diego, CA, September 8, 2016 – BioTheryX, Inc. (BTX), is developing next-generation drugs that selectively regulate the stability of disease-causing proteins to treat a broad range of diseases, including cancer and immune disorders. BioTheryX’s innovative approach to drug discovery exploits the exquisite specificity of the ubiquitin proteasome system (UPS). BioTheryX has entered into a strategic collaboration with Nobel laureate Dr. Aaron Ciechanover at the Rappaport Institute to employ advanced ubiquitin-directed proteomics to assist in elucidating direct protein targets and prognostic biomarkers for BTX’s proprietary small molecule Protein Homeostatic Modulators™ (PHMs™). This powerful new class of small molecule drugs will selectively modulate key therapeutically validated protein targets in oncology, immunology, inflammation, as well as emerging targets in the fields of immune-oncology and cancer stem cells. Dr. Ciechanover is a Distinguished Research Professor at the Rappaport institute for Biomedical Research-Technion-Israel Institute of Technology, and BioRap Technologies is its technology transfer arm. Professor Ciechanover, together with colleagues Drs. Avram Hershko and Irwin Rose, won the 2004 Nobel Prize in chemistry for the discovery of ubiquitin mediated protein degradation. Along with Hershko, he was also recognized with the prestigious Albert Lasker Award for Basic Medical Research (2000). Additionally, among many world renowned organizations, Dr. Ciechanover is a member of the USA National Academies of Sciences (NAS) and Medicine (NAM).
The BioTheryX team, led by Celgene Corp. founder David Stirling, were the developers of the remarkable IMiD® family of compounds while at Celgene. It is now known that the IMiDs® (a franchise of blood cancer compounds now exceeding $35 billion) work by promoting ubiquitin degradation of key protein targets in oncology, giving the BTX team the most commercial experience in the protein regulation field.
David Stirling, Chief Executive Officer, BioTheryX, commented, “BioTheryX is pleased and excited to be working with Professor Ciechanover, the “father” of the ubiquitin-proteasome field, to advance these exciting compounds into the clinic. Our proprietary PHMs are orally available, small molecule compounds which display potent and selective biological activities and excellent safety profiles. We believe BTX’s PHMs will have clinical utility in both cancer and immune disorders. Indeed, the lead compound in this series promotes selective degradation of a well-documented, clinically validated drug target more effectively than currently approved drugs, and this trajectory could represent a significant fast track to the clinic.”
Professor Aaron Ciechanover, Tumor and Vascular Biology Research Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, commented, “The platform discovered by BioTheryX is exciting and broad, and can be applied to any substrate at will. It opens a wide window to the development of novel therapeutic modalities to a broad array of diseases, including malignancies and neurodegenerative disorders. Therefore, we are excited to be part of this novel and promising emerging approach”
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiD® franchise of compounds which have improved the quality of life of so many cancer patients and their loved ones, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. The team’s core expertise is to discover and develop molecules that regulate protein homeostasis and stimulate the immune system to destroy cancers with minimal toxicities by utilizing enhanced biology-driven models. As a result, these novel drug candidates have large therapeutic windows. When coupled with clinically proven translational therapeutics targeting cancer and immune dysregulation, the result is a rapid delivery of new drugs to patients with unmet medical needs. For more information please visit www.biotheryx.com.
BioRap is the Rappaport Institute's technology transfer company led by Dr Orit Shaked and its liaison to industry, bringing promising scientific innovations generated at the Institute to collaboration with industry and commercialization. The company provides the legal and commercial frameworks for the inventions and innovations of RI researchers, protecting discoveries and innovations with patents, and working jointly with industry to bring scientific discovery to the market. For more information please visit www.bio-rap.com.
Media Contact for BioRap:Orit Shaked Biorap Technologies, Rappaport Research Institute
Tel: +972 (0)4829-5402
Mob: +972 (0)5476 52313 E-mail: email@example.com
Media Contact for BioTheryX:Lawrence Zaslow, President
Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological CancersJerusalem, Israel, May 4, 2016 – Yissum Research Development Company of the Hebrew University of Jerusalem announced today that it had signed an exclusive world-wide licensing and research agreement with BioTheryX, Inc., developer of novel protein degradation and immunomodulatory drugs for cancer and immune dysfunction, for the development and commercialization of drug candidates representing first-in-class therapy for both hematologic and solid malignancies. Financial terms of the license were not disclosed.
The novel technology was invented by Yinon Ben-Neriah, MD, PhD, Blumenthal Professor of Cancer Research, Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, with generous support by AMRF (The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation). Dr. Ben-Neriah’s and his team showed that inhibition of the clinically validated enzyme CKI-alpha, induces several tumor suppressor pathways, including a new type of DNA damage response and p53 activation. This provides a novel approach to treat a wide range of cancers, in particular selective types of hematological malignancies.
Prof. Yinon Ben-Neriah has recently received the 2016 Rappaport Prize for excellence in biomedical research, among others, for his ground breaking research on the relationship between chronic inflammation and cancer and the treatment of leukemia.
Based on their complementing expertise, BioTheryX and Yissum have agreed to join forces and focus on the selection and advancement of clinical candidates designed to inhibit CKI-alpha. Initial clinical focus for these candidates will be selective subtypes of myelodysplastic syndrome and acute myeloid leukemia that are not responsive to available cancer therapy.
In preclinical studies of acute leukemia, these clinical candidates showed a far greater therapeutic potential than any previously reported studies. Treatment of genetically-modified leukemic mice modeling poor-prognosis human acute myeloid leukemia, abolished the disease signs in the majority of the animals, without compromising the normal bone marrow, demonstrating that CKI-alpha inhibitors have a large therapeutic window and are unique in their capacity to specifically eliminate leukemia stem cells, including otherwise treatment-resistant stem cells - a strong indication of cancer cure.
Yaacov Michlin, President and Chief Executive Officer, Yissum, commented, “The treatment that was developed in Prof. Ben-Neriah’s lab is very different from other available therapies, both in its mechanism of action and its ability to eliminate leukemic stem cells, and thus in its therapeutic potential. In light of the successful pre-clinical studies, we believe that it offers a significant breakthrough, and we are very pleased to partner with BioTheryX in the development of new drug candidates for potential treatment of a variety of hematological indications. We believe that the combined know-how and research efforts of the teams at BioTheryX and the Hebrew University will facilitate new drug development, leading to significant advancement in the therapy of this class of devastating cancer diseases.”
David Stirling, Chief Executive Officer, BioTheryX, commented, “BioTheryX is particularly pleased to partner with the Hebrew University on this important project. Our team, having developed the remarkable IMiD® family of drugs while at Celgene, which have improved the quality of life of so many cancer patients and their loved ones, brings a deep wealth of experience to developing novel cancer therapies that modulate protein degradation and the immune system to target cancer causing proteins for destruction. We believe that these unique drug candidates from the Hebrew University will not only bring new treatment modalities to a variety of hematological cancers, but may provide the only option for those patients that relapse and become resistant to currently available therapies.”
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Products based on Hebrew University technologies that have been commercialized by Yissum currently generate $2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered over 9,325 patents covering 2,600 inventions; has licensed out 880 technologies and has spun out 110 companies including Avraham Pharmaceuticals, Betalin Therapeutics, CollPlant and Qlight Nanotech. Yissum’s business partners span the globe and include companies such as Syngenta, Monsanto, Roche, Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more. For further information please visit www.yissum.co.il.
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. The team’s core expertise is to discover and develop molecules that regulate protein homeostasis and stimulate the immune system to destroy cancers with minimal toxicities by utilizing enhanced biology-driven models. As a result, these novel drug candidates have large therapeutic windows. When coupled with clinically proven translational therapeutics targeting cancer and immune dysregulation, the result is a rapid delivery of new drugs to patients with unmet medical needs. For more information please visit www.biotheryx.com.
Media Contact for Yissum:Tsipi Haitovsky
Global Media Liaison, Yissum Ltd.
Media Contact for BioTheryX:Lawrence Zaslow, President